RNA Interference Research Report 2024: Global Market to Surpass $6.5 Billion by 2034, Fueled by Advancements in Delivery, Rising Investments, Strategic Collaborations, Government & Regulatory Backing - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "RNA Interference Market by Type, by Application, by End-user, and by Region" report has been added to ResearchAndMarkets.com's offering.

The global RNA interference (RNAi) market accounted for USD 1.23 billion in 2023 and is expected to reach USD 6.51 billion by 2034 with a CAGR of 16.33% during the forecast period 2024-2034.

The market will grow due to rising investments in RNAi research and development, increasing demand for RNAi therapeutics, improvements in RNAi delivery technologies, regulatory support for RNAi therapeutics, and strategic alliances and collaborations.

The potential of RNAi-based medicines to treat a variety of diseases, including as cancer, genetic disorders, infectious diseases, and rare illnesses, has drawn attention to them. RNA interference (RNAi) presents a viable target for medication development since it can specifically target genes that cause disease while protecting healthy cells. For instance, Dicerna Pharmaceuticals gave updates in January 2024 regarding their partnership with Novo Nordisk to create RNAi therapies for cardiometabolic illnesses associated with the liver.

North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of a mature biotechnology and pharmaceutical industry, strong research infrastructure, favorable regulatory environment, and high investments in RNA interference (RNAi) research and development.

Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of RNA interference (RNAi) technology in emerging economies, expanding biotechnology and pharmaceutical sectors, and rising investments in healthcare research and development. For instance, Ionis Pharmaceuticals stated in December 2023 that vupanorsen (ION449) would be the subject of a Phase 3 clinical trial for people with familial chylomicronemia syndrome (FCS).

By type, the siRNA segment accounted for the highest revenue-grossing segment in the global RNA interference (RNAi) market in 2023 owing to the high specificity, potency, and versatility of siRNA molecules in targeting disease-causing genes, driving their widespread adoption in therapeutic and research applications.

For instance, in January 2024, Alnylam Pharmaceuticals declared that patient enrolment in the HELIOS-A Phase 3 trial of vutrisiran for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) was completed. Additionally, the miRNA segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing understanding of the role of microRNAs in gene regulation and disease pathogenesis, coupled with advancements in delivery technologies enhancing their therapeutic potential.

By application, the drug discovery and development segment accounted for the highest revenue-grossing segment in the global RNA interference (RNAi) market in 2023 owing to the growing demand for RNAi technology in target validation, lead optimization, and preclinical studies, accelerating drug discovery timelines and reducing development costs. Additionally, the therapeutics segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding pipeline of RNAi-based drugs targeting various diseases, advancements in delivery systems enhancing efficacy, and increasing regulatory approvals paving the way for commercialization.

By end-user, the pharmaceutical and biotechnology companies segment accounted for the highest revenue-grossing segment in the global RNA interference (RNAi) market in 2023 owing to the significant investments in RNAi research and development, robust pipeline of RNAi therapeutics, and strategic partnerships driving innovation and commercialization efforts. Additionally, the contract research organizations segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing outsourcing of RNAi-related services by pharmaceutical and biotechnology companies, expanding demand for RNAi-based drug development and screening services, and advancements in RNAi technology driving research collaborations.

Key Attributes:

Report Attribute	Details
No. of Pages	200
Forecast Period	2023 - 2034
Estimated Market Value (USD) in 2023	$1.23 Billion
Forecasted Market Value (USD) by 2034	$6.51 Billion
Compound Annual Growth Rate	16.3%
Regions Covered	Global

Report Scope:

• Base Year: 2023
• Forecast Period: 2024-2034
• Study Coverage
• Market Forecast by Type, Application, and End-User
• Market Forecast for 5 Regions and 17+ Countries
• Exhaustive Company Profiles of the Top 10+ Major Market Players
• 20% Free Customization Available to Meet Your Exact Requirement

Company Profiles

• Alnylam Pharmaceuticals
• Arrowhead Pharmaceuticals
• Dicerna Pharmaceuticals
• Quark Pharmaceuticals
• Silence Therapeutics
• Ionis Pharmaceuticals
• Arcturus Therapeutics
• Sirnaomics Inc.
• Benitec Biopharma
• miRagen Therapeutics
• Olix Pharmaceuticals
• miRecule Inc.
• RXi Pharmaceuticals
• Sylentis
• Tacere Therapeutics

RNA Interference (RNAi) Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)

• dsRNA
• siRNA
• miRNA

RNA Interference (RNAi) Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)

• Drug Discovery and Development
• Therapeutics
• Agricultural Crop Modifications
• Others

RNA Interference (RNAi) Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Academia and Research Centers
• Others

RNA Interference (RNAi) Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of LATAM
• Middle East & Africa
• South Africa
• GCC
• Rest of MEA

For more information about this report visit https://www.researchandmarkets.com/r/5lq5u2

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.